Comparing two OCT scanners for people with ocular tumors
Official title: Ocular Imaging for Monitoring of Ocular Tumor Disease
Run by Memorial Sloan Kettering Cancer Center · NCT07449195 · Data updated 2026-11-12
This will try two different OCT imaging devices to see which makes clearer eye images for adults with ocular tumors.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | Memorial Sloan Kettering Cancer Center Academic / other |
| Locations | 7 sites (Basking Ridge, New Jersey and 6 other locations) |
| Status | Recruiting |
| Started | February 27, 2026 |
| Main results expected | February 27, 2028 |
| Study ends | February 27, 2028 |
| Registry record updated | May 13, 2026 |
| Trial ID | NCT07449195 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18 years) with at least one intraocular or ocular surface tumor who have a natural or intraocular lens, pupils that dilate to about 3 mm, clear media for retinal imaging, and the ability to fixate and sit still.
✕Probably not a fit
Patients with opaque lenses or other eye disease that prevents viewing the retina, pupils that cannot dilate to the required size, or those unable to fixate or remain still are unlikely to benefit from the imaging comparison.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional comparison obtains images of eyes with intraocular or ocular surface tumors using the Intalight Dream and the Heidelberg Spectralis OCT devices. Eligible eyes are dilated and imaged on both machines during clinic visits, and resulting scans are compared for image clarity, tumor detail, and ability to visualize the retina or lesion. The procedure is noninvasive and brief, requiring the patient to fixate and sit still for short periods. Findings will show whether one device provides more useful imaging for diagnosing or monitoring ocular tumors.
Why it matters
Potential benefit: If one device yields consistently clearer tumor images, clinicians could detect and follow ocular tumors more accurately without extra invasive testing.
How similar studies have gone: OCT is widely used and prior work shows it can image eye tumors and that device-to-device comparisons are informative, though direct comparisons focused specifically on ocular tumors are less common.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥18 years. * At least 1 eye that has an intraocular or ocular surface tumor. * The presence of a natural crystalline lens or intraocular lens. * Pupils that can dilate up to at least 3 mm in the study eyes. * The absence of opaque natural crystalline lenses or the presence of any ocular disease that prevents the view of the retina for imaging. * Patients must be able to fixate on the imaging target. * Patients must be able to sit still for a period of time (approximately 2 minutes). Exclusion Criteria: * Does not meet ALL of the above conditions
Where it's running
-
Memorial Sloan Kettering at Basking Ridge (Consent Only)
Basking Ridge, New Jersey, United States Recruiting -
Memorial Sloan Kettering Monmouth (Consent only)
Middletown, New Jersey, United States Recruiting -
Memorial Sloan Kettering Bergen (Consent Only)
Montvale, New Jersey, United States Recruiting -
Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Consent only)
Commack, New York, United States Recruiting -
Memorial Sloan Kettering Westchester (Consent Only)
Harrison, New York, United States Recruiting -
Memorial Sloan Kettering Cancer Center (All Protocol Activites)
New York, New York, United States Recruiting
Show 1 more location
-
Memorial Sloan Kettering Cancer Center @ Nassau (Consent only)
Uniondale, New York, United States Recruiting
Study contacts
- Principal investigator: Jasmine Francis, MD — Memorial Sloan Kettering Cancer Center
- Study coordinator: Jasmine Francis, MD
- Email: francij1@mskcc.org
- Phone: 212-639-7266
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Using advanced imaging technology during eye surgery
This study is testing a new imaging technology during eye surgery to see if it can help doctors perform better and improve outcomes for patients with retinal diseases.
-
Retifanlimab after chemoradiation for anal cancer
This study tests whether retifanlimab can help people with anal squamous cell carcinoma who have completed chemoradiation and still have residual disease.
-
Different skin care approaches to prevent skin reactions after mastectomy radiation
This study tests three standard skin care methods to see which best prevents radiation dermatitis in people who had a mastectomy and are receiving post-mastectomy radiation therapy.
-
Graft-versus-host disease after stem cell transplant: testing LBP-MARCO with ruxolitinib
We are testing whether combining LBP-MARCO with ruxolitinib is safe for adults with GVHD after a stem cell transplant.
-
68Ga-FAPI PET/MRI imaging to see if it can track breast cancer response to chemotherapy
This study tests whether a new imaging scan, 68Ga-FAPI PET/MRI, can show how well invasive breast cancer responds to neoadjuvant chemotherapy in adults.
-
Can we skip radiation after lumpectomy for low-risk HER2-positive breast cancer?
This study tests whether patients who had breast-conserving surgery and low-risk HER2-positive breast cancer can safely skip radiation therapy while receiving HER2-targeted treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.